Review



mouse monoclonal anti agr2  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology mouse monoclonal anti agr2
    Secreted <t>AGR2</t> promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Mouse Monoclonal Anti Agr2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti agr2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 40 article reviews
    mouse monoclonal anti agr2 - by Bioz Stars, 2026-04
    93/100 stars

    Images

    1) Product Images from "Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy"

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2024.101927

    Secreted AGR2 promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Figure Legend Snippet: Secreted AGR2 promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Techniques Used: Immunohistochemical staining, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, CRISPR, Knock-Out, Control, Derivative Assay, Staining, Standard Deviation

    Agr2 secretion correlates with desmoplastic reaction in genetic mouse models of PDAC (A) Schematic illustration of the genotypes for KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice. (B) Representative hematoxylin and eosin (H&E), Agr2, Krt19, and α-amylase-stained sections, along with α-SMA/BrdU-stained immunofluorescence images of pancreata from KC, KC; Agr2 −/− , and KC; Agr2 OE mice (scale bars: 50 μm; n = 12 mice per group). The images were scored and thereby quantified (right). (C) ELISA analysis of Agr2 levels in the serum of 8-week-old KC, KC; Agr2 −/− and KC; Agr2 OE mice ( n = 12 mice per group). (D) Western blot analysis of α-SMA, α-amylase, and Agr2 expression in the pancreata of KC, KC; Agr2 −/− , and KC; Agr2 OE mice ( n = 4 mice per group). (E) Schematic representation of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (F) Representative images of H&E staining, EGFP immunofluorescence, and IHC for Krt19, α-amylase, and α-SMA in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles (scale bars: 50 μm; n = 3 mice per group). The images were scored and thereby quantified (right). (G) ELISA analysis of Agr2 levels in the serum of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (H) Western blot analysis of α-SMA, α-amylase, Agr2, and EGFP expression in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (I and J) Schematic representation and survival curves for KC and KC; Agr2 −/− mice over a 1.5-year follow-up period. (K) PDAC incidence in KC (11/34, 32.4%) versus KC; Agr2 −/− mice (5/40, 12.5%). (L) ELISA analysis of Agr2 levels in the serum of KC and KC; Agr2 −/− mice with PDAC ( n = 5 mice per group). (M) Representative H&E-stained sections showing PDAC tumors in KC and KC; Agr2 −/− mice; Sirius red-stained sections showing collagen distribution in tumors; α-SMA/BrdU-stained immunofluorescence images depicting proliferative α-SMA-positive cells in tumors (scale bars: 50 μm; n = 5 mice per group). (N) Western blot analysis of α-SMA and Agr2 expression in tumors from KC mice and KC; Agr2 −/− mice ( n = 5 mice per group). Statistical significance for (B), (C), (G), and (F) was assessed using a one-way ANOVA with multiple comparisons test, (J) with a log rank test, (K) with a chi-squared test, and (L) and (M) with two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. Significance is denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. “ns” indicates no significance.
    Figure Legend Snippet: Agr2 secretion correlates with desmoplastic reaction in genetic mouse models of PDAC (A) Schematic illustration of the genotypes for KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice. (B) Representative hematoxylin and eosin (H&E), Agr2, Krt19, and α-amylase-stained sections, along with α-SMA/BrdU-stained immunofluorescence images of pancreata from KC, KC; Agr2 −/− , and KC; Agr2 OE mice (scale bars: 50 μm; n = 12 mice per group). The images were scored and thereby quantified (right). (C) ELISA analysis of Agr2 levels in the serum of 8-week-old KC, KC; Agr2 −/− and KC; Agr2 OE mice ( n = 12 mice per group). (D) Western blot analysis of α-SMA, α-amylase, and Agr2 expression in the pancreata of KC, KC; Agr2 −/− , and KC; Agr2 OE mice ( n = 4 mice per group). (E) Schematic representation of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (F) Representative images of H&E staining, EGFP immunofluorescence, and IHC for Krt19, α-amylase, and α-SMA in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles (scale bars: 50 μm; n = 3 mice per group). The images were scored and thereby quantified (right). (G) ELISA analysis of Agr2 levels in the serum of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (H) Western blot analysis of α-SMA, α-amylase, Agr2, and EGFP expression in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (I and J) Schematic representation and survival curves for KC and KC; Agr2 −/− mice over a 1.5-year follow-up period. (K) PDAC incidence in KC (11/34, 32.4%) versus KC; Agr2 −/− mice (5/40, 12.5%). (L) ELISA analysis of Agr2 levels in the serum of KC and KC; Agr2 −/− mice with PDAC ( n = 5 mice per group). (M) Representative H&E-stained sections showing PDAC tumors in KC and KC; Agr2 −/− mice; Sirius red-stained sections showing collagen distribution in tumors; α-SMA/BrdU-stained immunofluorescence images depicting proliferative α-SMA-positive cells in tumors (scale bars: 50 μm; n = 5 mice per group). (N) Western blot analysis of α-SMA and Agr2 expression in tumors from KC mice and KC; Agr2 −/− mice ( n = 5 mice per group). Statistical significance for (B), (C), (G), and (F) was assessed using a one-way ANOVA with multiple comparisons test, (J) with a log rank test, (K) with a chi-squared test, and (L) and (M) with two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. Significance is denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. “ns” indicates no significance.

    Techniques Used: Staining, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Injection, Two Tailed Test

    IGF1 promotes the secretion of AGR2, which in turn enhances the presentation of the IGF1R on the cell surface (A) The Venn diagram of the upper panel illustrates the count of genes down-regulated in Capan2 and Panc1 cells post AGR2 knockout. The Gene Ontology (GO) analysis of the lower panel identifies enriched biological processes, notably “regulation of IGF receptor signaling pathway” at transcriptional levels, after AGR2 knockout in these cell lines. (B) Western blot and quantitative reverse-transcription PCR (qRT-PCR) analyses assess IGF1R and AGR2 expression in Capan2 and Panc1 cells following AGR2 knockout via the CRISPR-Cas9 system (performed in triplicate). (C) Flow cytometry (FACS) quantifies cell membrane surface expression of IGF1R in Capan2 and Panc1 cells after AGR2 knockout (performed in triplicate). (D) Co-immunoprecipitation assays reveal AGR2’s interaction with pro-IGF1R in Capan2 and Panc1 cells (performed in triplicate). (E) Immunofluorescence imaging displays AGR2 and IGF1R distribution and ER labeling in Panc1 cells (scale bars: 50 μm). (F) Western blot analysis of IGF1R and AGR2 in Panc1 and Capan2 cells with controls (original cell lines), AGR2-knockout (AGR2 KO ) post-expression of AGR2 WT , AGR2 ΔNLS , AGR2 ΔSP , and AGR2 C81A mutation (performed in triplicate). (G) Western blot analysis of IGF1R expression in AGR2 in Panc1 and Capan2 cells with AGR2 knockout (KO) treated with 3-methyladenine (3-MA) (15 mM), bafilomycin A1 (30 nM), chloroquine (20 mM), MLN4929 (1 mM), or MG132 (5 mM) for 12 h (performed in triplicate). (H) Western blot analysis of IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 following 12 h of serum starvation and subsequent IGF1 stimulation (50 ng/mL, performed in triplicate). (I) ELISA measures AGR2 secretion after serum starvation and treatment with PPP (1 μM) and IGF1 (50 ng/mL) over time (performed in triplicate). (J) Identification of potential c-JUN-binding sites within the AGR2 promoter region. (K) Western blot analysis of c-JUN, phosphorylated c-JUN, and AGR2 expression following c-JUN knockdown and IGF1 stimulation over time (performed in triplicate). (L) Western blot shows c-JUN, phosphorylated c-JUN, and AGR2 expression post anisomycin treatment over time (performed in triplicate). (M) Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) demonstrates c-JUN enrichment at AGR2’s transcription start sites (TSSs) before and after IGF1 treatment (performed in triplicate). (N) Integrative Genomics Viewer (IGV) tracks display c-JUN peaks in AGR2’s promoter region post IGF1 treatment. (O) Dual-luciferase reporter assays in Capan2 and Panc1 cells evaluate AGR2 promoter activity under various lengths and site-specific mutations after IGF1 treatment (performed in triplicate). Statistical analyses: (B) and (C) used a one-way ANOVA with multiple comparisons. (I), (M), (N), and (O) were analyzed using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD, with significance marked as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and “ns” indicates no significance.
    Figure Legend Snippet: IGF1 promotes the secretion of AGR2, which in turn enhances the presentation of the IGF1R on the cell surface (A) The Venn diagram of the upper panel illustrates the count of genes down-regulated in Capan2 and Panc1 cells post AGR2 knockout. The Gene Ontology (GO) analysis of the lower panel identifies enriched biological processes, notably “regulation of IGF receptor signaling pathway” at transcriptional levels, after AGR2 knockout in these cell lines. (B) Western blot and quantitative reverse-transcription PCR (qRT-PCR) analyses assess IGF1R and AGR2 expression in Capan2 and Panc1 cells following AGR2 knockout via the CRISPR-Cas9 system (performed in triplicate). (C) Flow cytometry (FACS) quantifies cell membrane surface expression of IGF1R in Capan2 and Panc1 cells after AGR2 knockout (performed in triplicate). (D) Co-immunoprecipitation assays reveal AGR2’s interaction with pro-IGF1R in Capan2 and Panc1 cells (performed in triplicate). (E) Immunofluorescence imaging displays AGR2 and IGF1R distribution and ER labeling in Panc1 cells (scale bars: 50 μm). (F) Western blot analysis of IGF1R and AGR2 in Panc1 and Capan2 cells with controls (original cell lines), AGR2-knockout (AGR2 KO ) post-expression of AGR2 WT , AGR2 ΔNLS , AGR2 ΔSP , and AGR2 C81A mutation (performed in triplicate). (G) Western blot analysis of IGF1R expression in AGR2 in Panc1 and Capan2 cells with AGR2 knockout (KO) treated with 3-methyladenine (3-MA) (15 mM), bafilomycin A1 (30 nM), chloroquine (20 mM), MLN4929 (1 mM), or MG132 (5 mM) for 12 h (performed in triplicate). (H) Western blot analysis of IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 following 12 h of serum starvation and subsequent IGF1 stimulation (50 ng/mL, performed in triplicate). (I) ELISA measures AGR2 secretion after serum starvation and treatment with PPP (1 μM) and IGF1 (50 ng/mL) over time (performed in triplicate). (J) Identification of potential c-JUN-binding sites within the AGR2 promoter region. (K) Western blot analysis of c-JUN, phosphorylated c-JUN, and AGR2 expression following c-JUN knockdown and IGF1 stimulation over time (performed in triplicate). (L) Western blot shows c-JUN, phosphorylated c-JUN, and AGR2 expression post anisomycin treatment over time (performed in triplicate). (M) Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) demonstrates c-JUN enrichment at AGR2’s transcription start sites (TSSs) before and after IGF1 treatment (performed in triplicate). (N) Integrative Genomics Viewer (IGV) tracks display c-JUN peaks in AGR2’s promoter region post IGF1 treatment. (O) Dual-luciferase reporter assays in Capan2 and Panc1 cells evaluate AGR2 promoter activity under various lengths and site-specific mutations after IGF1 treatment (performed in triplicate). Statistical analyses: (B) and (C) used a one-way ANOVA with multiple comparisons. (I), (M), (N), and (O) were analyzed using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD, with significance marked as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and “ns” indicates no significance.

    Techniques Used: Knock-Out, Western Blot, Reverse Transcription, Quantitative RT-PCR, Expressing, CRISPR, Flow Cytometry, Membrane, Immunoprecipitation, Immunofluorescence, Imaging, Labeling, Mutagenesis, Enzyme-linked Immunosorbent Assay, Binding Assay, Knockdown, Chromatin Immunoprecipitation, Real-time Polymerase Chain Reaction, Luciferase, Activity Assay, Two Tailed Test

    Secreted AGR2 promotes IGF1 production from CAFs via the Wnt/β-catenin pathway (A) Western blot analysis evaluates AGR2 and IGF1 levels in three human PDAC-derived CAFs and three PDAC cell lines (Capan2, HPAC, and Panc1) across three independent experiments. (B) qRT-PCR analysis of IGF1 expression and supernatant ELISA analyses of IGF1 secretion in human PDAC-derived CAFs co-cultured with two human PDAC organoids and with or without treatment with Agr2-neutralizing antibody (5 μg/mL) for 48 h ( n = 3 independent experiments). (C) qRT-PCR assesses IGF1 expression in PDAC-derived CAFs co-cultured with AGR2-knockout Capan2 and Panc1 cells, following re-expression of AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP for 48 h (upper); Western blot analysis investigates IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 levels in AGR2-knockout Capan2 and Panc1 cells after co-culture with PDAC-derived CAFs (lower, n = 3 independent experiments). (D) qRT-PCR explores IGF1 expression in two PDAC-derived CAFs after treatment with rAGR2 (500 ng/mL), rTGF-β1 (4 μg/mL), and rIL-1α (200 ng/mL) for 24 h ( n = 3 independent experiments). (E) Supernatant analysis quantifies collagen levels in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (F) Transwell assays examine cell migration in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (G) Left: scRNA-seq identifies iCAFs and myCAFs within 16 PDAC tissues (GEO: GSE155698), showing iCAFs with elevated IGF1 expression (>mean value). Right: volcano plot displays genes differentially expressed between IGF1 high and IGF1 low CAFs (FDR < 0.01; log 2 FC > 0.5), accompanied by KEGG pathway analysis of the IGF1-CAF signature. (H) Principal component analysis (PCA) of transcriptomic data from CAFs treated with rAGR2, rTGF-β1, and rIL-1α ( n = 3 per group). (I) A heatmap shows genes significantly upregulated in CAFs after treatment with rAGR2, rTGF-β1, and rIL-1α (FDR < 0.01; log2FC > 0.5; left). Bioplant pathway analysis elucidates upregulated gene pathways post rAGR2 treatment in CAFs (right). (J) Identification of potential lymphoid enhancer binding factor 1 (LEF1)-binding sites within the IGF1 promoter region. (K) Western blot analysis shows β-catenin expression in both nuclear and cytoplasmic fractions of PDAC-derived CAFs after AGR2 stimulation (500 ng/mL) for 0.5, 1, 3, and 6 h ( n = 3 independent experiments). (L) Western blot and qRT-PCR analyses evaluate β-catenin and IGF1 levels in PDAC-derived CAFs post β-catenin knockdown or following treatment with ICG-001 (Wnt pathway inhibitor) and rAGR2 (500 ng/mL) for 24 h (M) Luciferase reporter assays in three PDAC-derived CAFs transfected with wild-type and site-specific mutagenized IGF1 promoter sequences based on (J) predictions, post rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). Statistical analysis: one-way ANOVA with multiple comparisons test was used for (B), (C), (D), and (L); two-tailed, unpaired Student’s t tests were employed for (E), (F), and (M). Data are presented as mean ± SD, with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 indicating levels of statistical significance.
    Figure Legend Snippet: Secreted AGR2 promotes IGF1 production from CAFs via the Wnt/β-catenin pathway (A) Western blot analysis evaluates AGR2 and IGF1 levels in three human PDAC-derived CAFs and three PDAC cell lines (Capan2, HPAC, and Panc1) across three independent experiments. (B) qRT-PCR analysis of IGF1 expression and supernatant ELISA analyses of IGF1 secretion in human PDAC-derived CAFs co-cultured with two human PDAC organoids and with or without treatment with Agr2-neutralizing antibody (5 μg/mL) for 48 h ( n = 3 independent experiments). (C) qRT-PCR assesses IGF1 expression in PDAC-derived CAFs co-cultured with AGR2-knockout Capan2 and Panc1 cells, following re-expression of AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP for 48 h (upper); Western blot analysis investigates IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 levels in AGR2-knockout Capan2 and Panc1 cells after co-culture with PDAC-derived CAFs (lower, n = 3 independent experiments). (D) qRT-PCR explores IGF1 expression in two PDAC-derived CAFs after treatment with rAGR2 (500 ng/mL), rTGF-β1 (4 μg/mL), and rIL-1α (200 ng/mL) for 24 h ( n = 3 independent experiments). (E) Supernatant analysis quantifies collagen levels in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (F) Transwell assays examine cell migration in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (G) Left: scRNA-seq identifies iCAFs and myCAFs within 16 PDAC tissues (GEO: GSE155698), showing iCAFs with elevated IGF1 expression (>mean value). Right: volcano plot displays genes differentially expressed between IGF1 high and IGF1 low CAFs (FDR < 0.01; log 2 FC > 0.5), accompanied by KEGG pathway analysis of the IGF1-CAF signature. (H) Principal component analysis (PCA) of transcriptomic data from CAFs treated with rAGR2, rTGF-β1, and rIL-1α ( n = 3 per group). (I) A heatmap shows genes significantly upregulated in CAFs after treatment with rAGR2, rTGF-β1, and rIL-1α (FDR < 0.01; log2FC > 0.5; left). Bioplant pathway analysis elucidates upregulated gene pathways post rAGR2 treatment in CAFs (right). (J) Identification of potential lymphoid enhancer binding factor 1 (LEF1)-binding sites within the IGF1 promoter region. (K) Western blot analysis shows β-catenin expression in both nuclear and cytoplasmic fractions of PDAC-derived CAFs after AGR2 stimulation (500 ng/mL) for 0.5, 1, 3, and 6 h ( n = 3 independent experiments). (L) Western blot and qRT-PCR analyses evaluate β-catenin and IGF1 levels in PDAC-derived CAFs post β-catenin knockdown or following treatment with ICG-001 (Wnt pathway inhibitor) and rAGR2 (500 ng/mL) for 24 h (M) Luciferase reporter assays in three PDAC-derived CAFs transfected with wild-type and site-specific mutagenized IGF1 promoter sequences based on (J) predictions, post rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). Statistical analysis: one-way ANOVA with multiple comparisons test was used for (B), (C), (D), and (L); two-tailed, unpaired Student’s t tests were employed for (E), (F), and (M). Data are presented as mean ± SD, with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 indicating levels of statistical significance.

    Techniques Used: Western Blot, Derivative Assay, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, Cell Culture, Knock-Out, Co-Culture Assay, Migration, Binding Assay, Knockdown, Luciferase, Transfection, Two Tailed Test

    High serum levels of AGR2 and IGF1 are associated with enhanced desmoplastic reactions and immunosuppression in PDAC (A) ELISA analysis of Igf1 in serum from 8-week-old KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice reveals a significant difference (left, n = 12 mice per group). Comparison between KC mice and KC; Agr2 −/− mice with PDAC also shows marked differences (right, n = 5 mice per group). (B) Serum levels of AGR2 and IGF1 exhibit a correlation in 145 human patients with PDAC, analyzed using Pearson’s correlation coefficient. (C) IHC images display α-SMA, podoplanin (PDPN), collagen, and IL-6 positivity in tumor areas, comparing AGR2 high ; IGF1 high samples with AGR2 low ; IGF1 low samples, demonstrating a difference in desmoplastic reaction. (D) IHC images illustrate the differential presence of CD3, CD8, CD4, FOXP3, CD68, CD206, and CD20-positive cells in tumors between AGR2 high ; IGF1 high samples and AGR2 low ; IGF1 low samples, indicating variations in immune cell infiltration (scale bars: 50 μm). (E) IHC imaging further reveals the distribution of Cd3, Cd8, Cd4, Foxp3, B220, F4/80, and Cd206-positive cells in tumors from KC mice versus KC; Agr2 −/− mice, emphasizing differences in immunological responses (scale bars: 50 μm). p values in left of (A) was calculated using a one-way ANOVA with a multiple comparisons test, p values in right of (A), (C), (D), and (E) were calculated using two-tailed, unpaired Student’s t tests, and correlation coefficient in (B) was calculated using Pearson’s correlation coefficient. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. ns, no significance.
    Figure Legend Snippet: High serum levels of AGR2 and IGF1 are associated with enhanced desmoplastic reactions and immunosuppression in PDAC (A) ELISA analysis of Igf1 in serum from 8-week-old KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice reveals a significant difference (left, n = 12 mice per group). Comparison between KC mice and KC; Agr2 −/− mice with PDAC also shows marked differences (right, n = 5 mice per group). (B) Serum levels of AGR2 and IGF1 exhibit a correlation in 145 human patients with PDAC, analyzed using Pearson’s correlation coefficient. (C) IHC images display α-SMA, podoplanin (PDPN), collagen, and IL-6 positivity in tumor areas, comparing AGR2 high ; IGF1 high samples with AGR2 low ; IGF1 low samples, demonstrating a difference in desmoplastic reaction. (D) IHC images illustrate the differential presence of CD3, CD8, CD4, FOXP3, CD68, CD206, and CD20-positive cells in tumors between AGR2 high ; IGF1 high samples and AGR2 low ; IGF1 low samples, indicating variations in immune cell infiltration (scale bars: 50 μm). (E) IHC imaging further reveals the distribution of Cd3, Cd8, Cd4, Foxp3, B220, F4/80, and Cd206-positive cells in tumors from KC mice versus KC; Agr2 −/− mice, emphasizing differences in immunological responses (scale bars: 50 μm). p values in left of (A) was calculated using a one-way ANOVA with a multiple comparisons test, p values in right of (A), (C), (D), and (E) were calculated using two-tailed, unpaired Student’s t tests, and correlation coefficient in (B) was calculated using Pearson’s correlation coefficient. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. ns, no significance.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Comparison, Imaging, Two Tailed Test

    Combined targeting attenuates desmoplastic reaction and normalizes immunosuppressive microenvironment (A) Western blot analysis reveals Agr2 and Igf1 levels in PSCs isolated from wild-type mice and three mouse PDAC cell lines, highlighting the differential expression patterns. (B) Schematic diagram shows the therapeutic strategy of combining IGF1R inhibitor and AGR2-neutralizing antibody. (C) ELISA and qRT-PCR analyses demonstrate Igf1 levels in PSCs co-cultured with KPC PDAC-derived organoids. The impact of treatments with the IGF1R inhibitor (PPP; 1 μM), Agr2-neutralizing antibody (5 μg/mL) alone, or their combination for 48 h is shown ( n = 3 independent experiments). (D) Western blot results display the expression levels of p-Igf1r, Igf1r, c-Jun, p-c-Jun, Akt, p-Akt, Erk, p-Erk, and Agr2 in mouse PDAC-derived organoids after co-culture with PSC cells and subsequent treatments as mentioned in (C) ( n = 3 independent experiments). (E) Representative images and quantitative analyses show the growth dynamics of PDAC organoids co-cultured with PSC cells under various treatment conditions over 0, 24, 48, and 96 h (scale bars: 50 μm, n = 3 independent experiments). (F) Tumor volume comparisons in KPC mice post caerulein-induced acute pancreatitis and subsequent treatments with Agr2 antibody (4 mg/kg; intraperitoneally [i.p.], three times per week for 2 weeks), PPP (20 mg/kg; i.p., three times per week for 2 weeks), or their combination ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (G) ELISA quantification of Agr2, Igf1, Il-1α, Lif, GM-CSF, and Il-6 in serum samples from the four groups of KPC mice underscores the systemic effects of the treatment modalities on cytokine levels ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (H and I) Representative stained sections and quantitative statistics of H&E, Pdpn, α-SMA, collagen, Cd3, Cd4, Foxp3, B220, and Cd206-positive cells within PDAC tumors (scale bars: 50 μm, n = 5 mice per group). (J) Representative IHC highlights CD8-positive cells in lymph nodes adjacent to the tumors (scale bars: 50 μm). p values in (C), (F), and (G) were calculated using a one-way ANOVA with a multiple comparisons test, and p values in (H) and (I) were calculated using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Figure Legend Snippet: Combined targeting attenuates desmoplastic reaction and normalizes immunosuppressive microenvironment (A) Western blot analysis reveals Agr2 and Igf1 levels in PSCs isolated from wild-type mice and three mouse PDAC cell lines, highlighting the differential expression patterns. (B) Schematic diagram shows the therapeutic strategy of combining IGF1R inhibitor and AGR2-neutralizing antibody. (C) ELISA and qRT-PCR analyses demonstrate Igf1 levels in PSCs co-cultured with KPC PDAC-derived organoids. The impact of treatments with the IGF1R inhibitor (PPP; 1 μM), Agr2-neutralizing antibody (5 μg/mL) alone, or their combination for 48 h is shown ( n = 3 independent experiments). (D) Western blot results display the expression levels of p-Igf1r, Igf1r, c-Jun, p-c-Jun, Akt, p-Akt, Erk, p-Erk, and Agr2 in mouse PDAC-derived organoids after co-culture with PSC cells and subsequent treatments as mentioned in (C) ( n = 3 independent experiments). (E) Representative images and quantitative analyses show the growth dynamics of PDAC organoids co-cultured with PSC cells under various treatment conditions over 0, 24, 48, and 96 h (scale bars: 50 μm, n = 3 independent experiments). (F) Tumor volume comparisons in KPC mice post caerulein-induced acute pancreatitis and subsequent treatments with Agr2 antibody (4 mg/kg; intraperitoneally [i.p.], three times per week for 2 weeks), PPP (20 mg/kg; i.p., three times per week for 2 weeks), or their combination ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (G) ELISA quantification of Agr2, Igf1, Il-1α, Lif, GM-CSF, and Il-6 in serum samples from the four groups of KPC mice underscores the systemic effects of the treatment modalities on cytokine levels ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (H and I) Representative stained sections and quantitative statistics of H&E, Pdpn, α-SMA, collagen, Cd3, Cd4, Foxp3, B220, and Cd206-positive cells within PDAC tumors (scale bars: 50 μm, n = 5 mice per group). (J) Representative IHC highlights CD8-positive cells in lymph nodes adjacent to the tumors (scale bars: 50 μm). p values in (C), (F), and (G) were calculated using a one-way ANOVA with a multiple comparisons test, and p values in (H) and (I) were calculated using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Techniques Used: Western Blot, Isolation, Expressing, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Cell Culture, Derivative Assay, Co-Culture Assay, Control, Staining, Two Tailed Test


    Figure Legend Snippet:

    Techniques Used: Virus, Recombinant, Control, Enzyme-linked Immunosorbent Assay, Isolation, Membrane, Protein Extraction, Chromatin Immunoprecipitation, Bicinchoninic Acid Protein Assay, Sircol Collagen Assay, Luciferase, RNA Sequencing Assay, Sequencing, Expressing, Real-time Polymerase Chain Reaction, shRNA, Plasmid Preparation, Software, Flow Cytometry



    Similar Products

    93
    Santa Cruz Biotechnology mouse monoclonal anti agr2
    Secreted <t>AGR2</t> promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Mouse Monoclonal Anti Agr2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti agr2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse monoclonal anti agr2 - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology mouse anti-agr2 clone 6c5
    Secreted <t>AGR2</t> promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Mouse Anti Agr2 Clone 6c5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-agr2 clone 6c5/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse anti-agr2 clone 6c5 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology mouse anti agr2
    Secreted <t>AGR2</t> promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Mouse Anti Agr2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti agr2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse anti agr2 - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology mouse agr2
    A IRE1β and <t>AGR2</t> expression in cell lines. Proteins were extracted and probed for IRE1β expression and AGR2 expression via immunoblot. Tubulin was used as a loading control. B Photographs showing the phenotype of cultures overexpressing IRE1β-FLAG in IRE1α wild-type ( ERN1 +/+ ) and IRE1α deficient ( ERN1 -/- ) cells. Left panels show untreated cultures, middle panels show cultures treated with 1μg/ml doxycycline for 72 hours, right panels show cultures treated with both 1μg/ml doxycycline and 1μM IRE1 endonuclease inhibitor 4μ8C. C Quantification of IRE1β transgene expression over time in Calu-1 ERN -/-IRE1βFLAG-DOX and LS174T ERN -/- IRE1βFLAG-DOX cells by western blot. Cultures were treated with 1μg/ml doxycycline for the indicated times, protein lysates were probed for IRE1β-FLAG expression and tubulin as a loading control.
    Mouse Agr2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse agr2/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse agr2 - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    90
    Abnova anti-agr2 mouse ab
    Workflow of <t>AGR2</t> pull-down (PD) methods and protein-level analysis. A, two different cell lines were used for AGR2 PD. Breast cancer cell line T47D, of which endogenously expressed AGR2 protein underwent DSP crosslinking and PD with AGR2-specific E7 peptide and untargeted control peptide F4. Cells without DSP treatment served as a control. Corresponding MS data were quantified using label-free quantification (LFQ). H1299 lung carcinoma cell line was stably transfected with vector carrying coding sequence of AGR2. AGR2 positive clone was labeled with heavy (R10K8) SILAC medium, whereas parental H1299 served as a control and was maintained in light (R0K0) SILAC medium. These cells underwent DSP crosslinking, and lysates were, according to total protein content, equally mixed into one sample, and PD was done with E7 (AGR2 specific) and F4 (control) peptides again. MS data were quantified using SILAC approach. B and C, protein levels of AGR2 were detected in all input samples (20 μg of total protein per well) as well as in eluted proteins (10 μl of eluates per well) using immunoblotting with anti-AGR2 and antiactin antibodies, which served as a loading control. Numbers under the bands represent integral absorbance (INT∗mm 2 ∗10 3 ) obtained by Quantity One software (Bio-Rad). AGR2, anterior gradient 2; DSP, dithiobis[succinimidylpropionate]; MS, mass spectrometry; SILAC, stable isotope labeling with amino acids in cell culture.
    Anti Agr2 Mouse Ab, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-agr2 mouse ab/product/Abnova
    Average 90 stars, based on 1 article reviews
    anti-agr2 mouse ab - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Abnova mouse anti-agr2
    Workflow of <t>AGR2</t> pull-down (PD) methods and protein-level analysis. A, two different cell lines were used for AGR2 PD. Breast cancer cell line T47D, of which endogenously expressed AGR2 protein underwent DSP crosslinking and PD with AGR2-specific E7 peptide and untargeted control peptide F4. Cells without DSP treatment served as a control. Corresponding MS data were quantified using label-free quantification (LFQ). H1299 lung carcinoma cell line was stably transfected with vector carrying coding sequence of AGR2. AGR2 positive clone was labeled with heavy (R10K8) SILAC medium, whereas parental H1299 served as a control and was maintained in light (R0K0) SILAC medium. These cells underwent DSP crosslinking, and lysates were, according to total protein content, equally mixed into one sample, and PD was done with E7 (AGR2 specific) and F4 (control) peptides again. MS data were quantified using SILAC approach. B and C, protein levels of AGR2 were detected in all input samples (20 μg of total protein per well) as well as in eluted proteins (10 μl of eluates per well) using immunoblotting with anti-AGR2 and antiactin antibodies, which served as a loading control. Numbers under the bands represent integral absorbance (INT∗mm 2 ∗10 3 ) obtained by Quantity One software (Bio-Rad). AGR2, anterior gradient 2; DSP, dithiobis[succinimidylpropionate]; MS, mass spectrometry; SILAC, stable isotope labeling with amino acids in cell culture.
    Mouse Anti Agr2, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-agr2/product/Abnova
    Average 90 stars, based on 1 article reviews
    mouse anti-agr2 - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Secreted AGR2 promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: Secreted AGR2 promotes pancreatic carcinogenesis by activating CAFs (A) Representative immunohistochemical (IHC) images demonstrate AGR2-positive and -negative PDAC tumors (scale bars: 50 μm). (B) Survival curves of patients categorized by AGR2 expression in PDAC tumor samples via IHC ( n = 99). (C) Survival curves of patients stratified according to median AGR2 levels, measured by ELISA, in serum from individuals with PDAC ( n = 172). (D) Western blot analyses of AGR2 expression in human PDAC cell lines (Capan2 and Panc1) following CRISPR-Cas9-mediated AGR2 knockout (performed in triplicate). (E) Images and volumes of control versus AGR2-knockout subcutaneous xenografts derived from Capan2 and Panc1 cell lines in nude mice ( n = 5 per group). (F) Subcutaneous xenografts from AGR2-knockout Capan2 and Panc1 cells (AGR2 KO ), following re-expression of wild-type AGR2 (AGR2 WT ), AGR2 lacking a nuclear localization signal (AGR2 ΔNLS ), and AGR2 lacking a signal peptide (AGR2 ΔSP ) ( n = 4 per group). (G) ELISA analyses of the supernatant from AGR2-knockout Capan2 and Panc1 cells re-expressing AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP (performed in triplicate). (H) Representative IHC images and quantification of alpha-smooth muscle actin (α-SMA) staining score and collagen score within xenograft tumors across the four groups ( n = 4 per group, scale bars: 50 μm). Statistical significance was determined using a log rank test for (B) and (C) and a one-way ANOVA with multiple comparisons test for (E) through (H). Data are presented as mean ± standard deviation (SD). Significance levels are indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Immunohistochemical staining, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, CRISPR, Knock-Out, Control, Derivative Assay, Staining, Standard Deviation

    Agr2 secretion correlates with desmoplastic reaction in genetic mouse models of PDAC (A) Schematic illustration of the genotypes for KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice. (B) Representative hematoxylin and eosin (H&E), Agr2, Krt19, and α-amylase-stained sections, along with α-SMA/BrdU-stained immunofluorescence images of pancreata from KC, KC; Agr2 −/− , and KC; Agr2 OE mice (scale bars: 50 μm; n = 12 mice per group). The images were scored and thereby quantified (right). (C) ELISA analysis of Agr2 levels in the serum of 8-week-old KC, KC; Agr2 −/− and KC; Agr2 OE mice ( n = 12 mice per group). (D) Western blot analysis of α-SMA, α-amylase, and Agr2 expression in the pancreata of KC, KC; Agr2 −/− , and KC; Agr2 OE mice ( n = 4 mice per group). (E) Schematic representation of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (F) Representative images of H&E staining, EGFP immunofluorescence, and IHC for Krt19, α-amylase, and α-SMA in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles (scale bars: 50 μm; n = 3 mice per group). The images were scored and thereby quantified (right). (G) ELISA analysis of Agr2 levels in the serum of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (H) Western blot analysis of α-SMA, α-amylase, Agr2, and EGFP expression in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (I and J) Schematic representation and survival curves for KC and KC; Agr2 −/− mice over a 1.5-year follow-up period. (K) PDAC incidence in KC (11/34, 32.4%) versus KC; Agr2 −/− mice (5/40, 12.5%). (L) ELISA analysis of Agr2 levels in the serum of KC and KC; Agr2 −/− mice with PDAC ( n = 5 mice per group). (M) Representative H&E-stained sections showing PDAC tumors in KC and KC; Agr2 −/− mice; Sirius red-stained sections showing collagen distribution in tumors; α-SMA/BrdU-stained immunofluorescence images depicting proliferative α-SMA-positive cells in tumors (scale bars: 50 μm; n = 5 mice per group). (N) Western blot analysis of α-SMA and Agr2 expression in tumors from KC mice and KC; Agr2 −/− mice ( n = 5 mice per group). Statistical significance for (B), (C), (G), and (F) was assessed using a one-way ANOVA with multiple comparisons test, (J) with a log rank test, (K) with a chi-squared test, and (L) and (M) with two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. Significance is denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. “ns” indicates no significance.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: Agr2 secretion correlates with desmoplastic reaction in genetic mouse models of PDAC (A) Schematic illustration of the genotypes for KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice. (B) Representative hematoxylin and eosin (H&E), Agr2, Krt19, and α-amylase-stained sections, along with α-SMA/BrdU-stained immunofluorescence images of pancreata from KC, KC; Agr2 −/− , and KC; Agr2 OE mice (scale bars: 50 μm; n = 12 mice per group). The images were scored and thereby quantified (right). (C) ELISA analysis of Agr2 levels in the serum of 8-week-old KC, KC; Agr2 −/− and KC; Agr2 OE mice ( n = 12 mice per group). (D) Western blot analysis of α-SMA, α-amylase, and Agr2 expression in the pancreata of KC, KC; Agr2 −/− , and KC; Agr2 OE mice ( n = 4 mice per group). (E) Schematic representation of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (F) Representative images of H&E staining, EGFP immunofluorescence, and IHC for Krt19, α-amylase, and α-SMA in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles (scale bars: 50 μm; n = 3 mice per group). The images were scored and thereby quantified (right). (G) ELISA analysis of Agr2 levels in the serum of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (H) Western blot analysis of α-SMA, α-amylase, Agr2, and EGFP expression in the pancreata of KC mice injected with AAV-EGFP, AAV- Agr2 WT , and AAV- Agr2 ΔSP particles. (I and J) Schematic representation and survival curves for KC and KC; Agr2 −/− mice over a 1.5-year follow-up period. (K) PDAC incidence in KC (11/34, 32.4%) versus KC; Agr2 −/− mice (5/40, 12.5%). (L) ELISA analysis of Agr2 levels in the serum of KC and KC; Agr2 −/− mice with PDAC ( n = 5 mice per group). (M) Representative H&E-stained sections showing PDAC tumors in KC and KC; Agr2 −/− mice; Sirius red-stained sections showing collagen distribution in tumors; α-SMA/BrdU-stained immunofluorescence images depicting proliferative α-SMA-positive cells in tumors (scale bars: 50 μm; n = 5 mice per group). (N) Western blot analysis of α-SMA and Agr2 expression in tumors from KC mice and KC; Agr2 −/− mice ( n = 5 mice per group). Statistical significance for (B), (C), (G), and (F) was assessed using a one-way ANOVA with multiple comparisons test, (J) with a log rank test, (K) with a chi-squared test, and (L) and (M) with two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. Significance is denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. “ns” indicates no significance.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Staining, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Injection, Two Tailed Test

    IGF1 promotes the secretion of AGR2, which in turn enhances the presentation of the IGF1R on the cell surface (A) The Venn diagram of the upper panel illustrates the count of genes down-regulated in Capan2 and Panc1 cells post AGR2 knockout. The Gene Ontology (GO) analysis of the lower panel identifies enriched biological processes, notably “regulation of IGF receptor signaling pathway” at transcriptional levels, after AGR2 knockout in these cell lines. (B) Western blot and quantitative reverse-transcription PCR (qRT-PCR) analyses assess IGF1R and AGR2 expression in Capan2 and Panc1 cells following AGR2 knockout via the CRISPR-Cas9 system (performed in triplicate). (C) Flow cytometry (FACS) quantifies cell membrane surface expression of IGF1R in Capan2 and Panc1 cells after AGR2 knockout (performed in triplicate). (D) Co-immunoprecipitation assays reveal AGR2’s interaction with pro-IGF1R in Capan2 and Panc1 cells (performed in triplicate). (E) Immunofluorescence imaging displays AGR2 and IGF1R distribution and ER labeling in Panc1 cells (scale bars: 50 μm). (F) Western blot analysis of IGF1R and AGR2 in Panc1 and Capan2 cells with controls (original cell lines), AGR2-knockout (AGR2 KO ) post-expression of AGR2 WT , AGR2 ΔNLS , AGR2 ΔSP , and AGR2 C81A mutation (performed in triplicate). (G) Western blot analysis of IGF1R expression in AGR2 in Panc1 and Capan2 cells with AGR2 knockout (KO) treated with 3-methyladenine (3-MA) (15 mM), bafilomycin A1 (30 nM), chloroquine (20 mM), MLN4929 (1 mM), or MG132 (5 mM) for 12 h (performed in triplicate). (H) Western blot analysis of IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 following 12 h of serum starvation and subsequent IGF1 stimulation (50 ng/mL, performed in triplicate). (I) ELISA measures AGR2 secretion after serum starvation and treatment with PPP (1 μM) and IGF1 (50 ng/mL) over time (performed in triplicate). (J) Identification of potential c-JUN-binding sites within the AGR2 promoter region. (K) Western blot analysis of c-JUN, phosphorylated c-JUN, and AGR2 expression following c-JUN knockdown and IGF1 stimulation over time (performed in triplicate). (L) Western blot shows c-JUN, phosphorylated c-JUN, and AGR2 expression post anisomycin treatment over time (performed in triplicate). (M) Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) demonstrates c-JUN enrichment at AGR2’s transcription start sites (TSSs) before and after IGF1 treatment (performed in triplicate). (N) Integrative Genomics Viewer (IGV) tracks display c-JUN peaks in AGR2’s promoter region post IGF1 treatment. (O) Dual-luciferase reporter assays in Capan2 and Panc1 cells evaluate AGR2 promoter activity under various lengths and site-specific mutations after IGF1 treatment (performed in triplicate). Statistical analyses: (B) and (C) used a one-way ANOVA with multiple comparisons. (I), (M), (N), and (O) were analyzed using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD, with significance marked as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and “ns” indicates no significance.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: IGF1 promotes the secretion of AGR2, which in turn enhances the presentation of the IGF1R on the cell surface (A) The Venn diagram of the upper panel illustrates the count of genes down-regulated in Capan2 and Panc1 cells post AGR2 knockout. The Gene Ontology (GO) analysis of the lower panel identifies enriched biological processes, notably “regulation of IGF receptor signaling pathway” at transcriptional levels, after AGR2 knockout in these cell lines. (B) Western blot and quantitative reverse-transcription PCR (qRT-PCR) analyses assess IGF1R and AGR2 expression in Capan2 and Panc1 cells following AGR2 knockout via the CRISPR-Cas9 system (performed in triplicate). (C) Flow cytometry (FACS) quantifies cell membrane surface expression of IGF1R in Capan2 and Panc1 cells after AGR2 knockout (performed in triplicate). (D) Co-immunoprecipitation assays reveal AGR2’s interaction with pro-IGF1R in Capan2 and Panc1 cells (performed in triplicate). (E) Immunofluorescence imaging displays AGR2 and IGF1R distribution and ER labeling in Panc1 cells (scale bars: 50 μm). (F) Western blot analysis of IGF1R and AGR2 in Panc1 and Capan2 cells with controls (original cell lines), AGR2-knockout (AGR2 KO ) post-expression of AGR2 WT , AGR2 ΔNLS , AGR2 ΔSP , and AGR2 C81A mutation (performed in triplicate). (G) Western blot analysis of IGF1R expression in AGR2 in Panc1 and Capan2 cells with AGR2 knockout (KO) treated with 3-methyladenine (3-MA) (15 mM), bafilomycin A1 (30 nM), chloroquine (20 mM), MLN4929 (1 mM), or MG132 (5 mM) for 12 h (performed in triplicate). (H) Western blot analysis of IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 following 12 h of serum starvation and subsequent IGF1 stimulation (50 ng/mL, performed in triplicate). (I) ELISA measures AGR2 secretion after serum starvation and treatment with PPP (1 μM) and IGF1 (50 ng/mL) over time (performed in triplicate). (J) Identification of potential c-JUN-binding sites within the AGR2 promoter region. (K) Western blot analysis of c-JUN, phosphorylated c-JUN, and AGR2 expression following c-JUN knockdown and IGF1 stimulation over time (performed in triplicate). (L) Western blot shows c-JUN, phosphorylated c-JUN, and AGR2 expression post anisomycin treatment over time (performed in triplicate). (M) Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) demonstrates c-JUN enrichment at AGR2’s transcription start sites (TSSs) before and after IGF1 treatment (performed in triplicate). (N) Integrative Genomics Viewer (IGV) tracks display c-JUN peaks in AGR2’s promoter region post IGF1 treatment. (O) Dual-luciferase reporter assays in Capan2 and Panc1 cells evaluate AGR2 promoter activity under various lengths and site-specific mutations after IGF1 treatment (performed in triplicate). Statistical analyses: (B) and (C) used a one-way ANOVA with multiple comparisons. (I), (M), (N), and (O) were analyzed using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD, with significance marked as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and “ns” indicates no significance.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Knock-Out, Western Blot, Reverse Transcription, Quantitative RT-PCR, Expressing, CRISPR, Flow Cytometry, Membrane, Immunoprecipitation, Immunofluorescence, Imaging, Labeling, Mutagenesis, Enzyme-linked Immunosorbent Assay, Binding Assay, Knockdown, Chromatin Immunoprecipitation, Real-time Polymerase Chain Reaction, Luciferase, Activity Assay, Two Tailed Test

    Secreted AGR2 promotes IGF1 production from CAFs via the Wnt/β-catenin pathway (A) Western blot analysis evaluates AGR2 and IGF1 levels in three human PDAC-derived CAFs and three PDAC cell lines (Capan2, HPAC, and Panc1) across three independent experiments. (B) qRT-PCR analysis of IGF1 expression and supernatant ELISA analyses of IGF1 secretion in human PDAC-derived CAFs co-cultured with two human PDAC organoids and with or without treatment with Agr2-neutralizing antibody (5 μg/mL) for 48 h ( n = 3 independent experiments). (C) qRT-PCR assesses IGF1 expression in PDAC-derived CAFs co-cultured with AGR2-knockout Capan2 and Panc1 cells, following re-expression of AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP for 48 h (upper); Western blot analysis investigates IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 levels in AGR2-knockout Capan2 and Panc1 cells after co-culture with PDAC-derived CAFs (lower, n = 3 independent experiments). (D) qRT-PCR explores IGF1 expression in two PDAC-derived CAFs after treatment with rAGR2 (500 ng/mL), rTGF-β1 (4 μg/mL), and rIL-1α (200 ng/mL) for 24 h ( n = 3 independent experiments). (E) Supernatant analysis quantifies collagen levels in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (F) Transwell assays examine cell migration in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (G) Left: scRNA-seq identifies iCAFs and myCAFs within 16 PDAC tissues (GEO: GSE155698), showing iCAFs with elevated IGF1 expression (>mean value). Right: volcano plot displays genes differentially expressed between IGF1 high and IGF1 low CAFs (FDR < 0.01; log 2 FC > 0.5), accompanied by KEGG pathway analysis of the IGF1-CAF signature. (H) Principal component analysis (PCA) of transcriptomic data from CAFs treated with rAGR2, rTGF-β1, and rIL-1α ( n = 3 per group). (I) A heatmap shows genes significantly upregulated in CAFs after treatment with rAGR2, rTGF-β1, and rIL-1α (FDR < 0.01; log2FC > 0.5; left). Bioplant pathway analysis elucidates upregulated gene pathways post rAGR2 treatment in CAFs (right). (J) Identification of potential lymphoid enhancer binding factor 1 (LEF1)-binding sites within the IGF1 promoter region. (K) Western blot analysis shows β-catenin expression in both nuclear and cytoplasmic fractions of PDAC-derived CAFs after AGR2 stimulation (500 ng/mL) for 0.5, 1, 3, and 6 h ( n = 3 independent experiments). (L) Western blot and qRT-PCR analyses evaluate β-catenin and IGF1 levels in PDAC-derived CAFs post β-catenin knockdown or following treatment with ICG-001 (Wnt pathway inhibitor) and rAGR2 (500 ng/mL) for 24 h (M) Luciferase reporter assays in three PDAC-derived CAFs transfected with wild-type and site-specific mutagenized IGF1 promoter sequences based on (J) predictions, post rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). Statistical analysis: one-way ANOVA with multiple comparisons test was used for (B), (C), (D), and (L); two-tailed, unpaired Student’s t tests were employed for (E), (F), and (M). Data are presented as mean ± SD, with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 indicating levels of statistical significance.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: Secreted AGR2 promotes IGF1 production from CAFs via the Wnt/β-catenin pathway (A) Western blot analysis evaluates AGR2 and IGF1 levels in three human PDAC-derived CAFs and three PDAC cell lines (Capan2, HPAC, and Panc1) across three independent experiments. (B) qRT-PCR analysis of IGF1 expression and supernatant ELISA analyses of IGF1 secretion in human PDAC-derived CAFs co-cultured with two human PDAC organoids and with or without treatment with Agr2-neutralizing antibody (5 μg/mL) for 48 h ( n = 3 independent experiments). (C) qRT-PCR assesses IGF1 expression in PDAC-derived CAFs co-cultured with AGR2-knockout Capan2 and Panc1 cells, following re-expression of AGR2 WT , AGR2 ΔNLS , and AGR2 ΔSP for 48 h (upper); Western blot analysis investigates IGF1R, phosphorylated IGF1R, c-JUN, phosphorylated c-JUN, and AGR2 levels in AGR2-knockout Capan2 and Panc1 cells after co-culture with PDAC-derived CAFs (lower, n = 3 independent experiments). (D) qRT-PCR explores IGF1 expression in two PDAC-derived CAFs after treatment with rAGR2 (500 ng/mL), rTGF-β1 (4 μg/mL), and rIL-1α (200 ng/mL) for 24 h ( n = 3 independent experiments). (E) Supernatant analysis quantifies collagen levels in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (F) Transwell assays examine cell migration in two PDAC-derived CAFs following rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). (G) Left: scRNA-seq identifies iCAFs and myCAFs within 16 PDAC tissues (GEO: GSE155698), showing iCAFs with elevated IGF1 expression (>mean value). Right: volcano plot displays genes differentially expressed between IGF1 high and IGF1 low CAFs (FDR < 0.01; log 2 FC > 0.5), accompanied by KEGG pathway analysis of the IGF1-CAF signature. (H) Principal component analysis (PCA) of transcriptomic data from CAFs treated with rAGR2, rTGF-β1, and rIL-1α ( n = 3 per group). (I) A heatmap shows genes significantly upregulated in CAFs after treatment with rAGR2, rTGF-β1, and rIL-1α (FDR < 0.01; log2FC > 0.5; left). Bioplant pathway analysis elucidates upregulated gene pathways post rAGR2 treatment in CAFs (right). (J) Identification of potential lymphoid enhancer binding factor 1 (LEF1)-binding sites within the IGF1 promoter region. (K) Western blot analysis shows β-catenin expression in both nuclear and cytoplasmic fractions of PDAC-derived CAFs after AGR2 stimulation (500 ng/mL) for 0.5, 1, 3, and 6 h ( n = 3 independent experiments). (L) Western blot and qRT-PCR analyses evaluate β-catenin and IGF1 levels in PDAC-derived CAFs post β-catenin knockdown or following treatment with ICG-001 (Wnt pathway inhibitor) and rAGR2 (500 ng/mL) for 24 h (M) Luciferase reporter assays in three PDAC-derived CAFs transfected with wild-type and site-specific mutagenized IGF1 promoter sequences based on (J) predictions, post rAGR2 treatment (500 ng/mL) for 24 h ( n = 3 independent experiments). Statistical analysis: one-way ANOVA with multiple comparisons test was used for (B), (C), (D), and (L); two-tailed, unpaired Student’s t tests were employed for (E), (F), and (M). Data are presented as mean ± SD, with ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 indicating levels of statistical significance.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Western Blot, Derivative Assay, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, Cell Culture, Knock-Out, Co-Culture Assay, Migration, Binding Assay, Knockdown, Luciferase, Transfection, Two Tailed Test

    High serum levels of AGR2 and IGF1 are associated with enhanced desmoplastic reactions and immunosuppression in PDAC (A) ELISA analysis of Igf1 in serum from 8-week-old KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice reveals a significant difference (left, n = 12 mice per group). Comparison between KC mice and KC; Agr2 −/− mice with PDAC also shows marked differences (right, n = 5 mice per group). (B) Serum levels of AGR2 and IGF1 exhibit a correlation in 145 human patients with PDAC, analyzed using Pearson’s correlation coefficient. (C) IHC images display α-SMA, podoplanin (PDPN), collagen, and IL-6 positivity in tumor areas, comparing AGR2 high ; IGF1 high samples with AGR2 low ; IGF1 low samples, demonstrating a difference in desmoplastic reaction. (D) IHC images illustrate the differential presence of CD3, CD8, CD4, FOXP3, CD68, CD206, and CD20-positive cells in tumors between AGR2 high ; IGF1 high samples and AGR2 low ; IGF1 low samples, indicating variations in immune cell infiltration (scale bars: 50 μm). (E) IHC imaging further reveals the distribution of Cd3, Cd8, Cd4, Foxp3, B220, F4/80, and Cd206-positive cells in tumors from KC mice versus KC; Agr2 −/− mice, emphasizing differences in immunological responses (scale bars: 50 μm). p values in left of (A) was calculated using a one-way ANOVA with a multiple comparisons test, p values in right of (A), (C), (D), and (E) were calculated using two-tailed, unpaired Student’s t tests, and correlation coefficient in (B) was calculated using Pearson’s correlation coefficient. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. ns, no significance.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: High serum levels of AGR2 and IGF1 are associated with enhanced desmoplastic reactions and immunosuppression in PDAC (A) ELISA analysis of Igf1 in serum from 8-week-old KC mice, KC; Agr2 −/− mice, and KC; Agr2 OE mice reveals a significant difference (left, n = 12 mice per group). Comparison between KC mice and KC; Agr2 −/− mice with PDAC also shows marked differences (right, n = 5 mice per group). (B) Serum levels of AGR2 and IGF1 exhibit a correlation in 145 human patients with PDAC, analyzed using Pearson’s correlation coefficient. (C) IHC images display α-SMA, podoplanin (PDPN), collagen, and IL-6 positivity in tumor areas, comparing AGR2 high ; IGF1 high samples with AGR2 low ; IGF1 low samples, demonstrating a difference in desmoplastic reaction. (D) IHC images illustrate the differential presence of CD3, CD8, CD4, FOXP3, CD68, CD206, and CD20-positive cells in tumors between AGR2 high ; IGF1 high samples and AGR2 low ; IGF1 low samples, indicating variations in immune cell infiltration (scale bars: 50 μm). (E) IHC imaging further reveals the distribution of Cd3, Cd8, Cd4, Foxp3, B220, F4/80, and Cd206-positive cells in tumors from KC mice versus KC; Agr2 −/− mice, emphasizing differences in immunological responses (scale bars: 50 μm). p values in left of (A) was calculated using a one-way ANOVA with a multiple comparisons test, p values in right of (A), (C), (D), and (E) were calculated using two-tailed, unpaired Student’s t tests, and correlation coefficient in (B) was calculated using Pearson’s correlation coefficient. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. ns, no significance.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Enzyme-linked Immunosorbent Assay, Comparison, Imaging, Two Tailed Test

    Combined targeting attenuates desmoplastic reaction and normalizes immunosuppressive microenvironment (A) Western blot analysis reveals Agr2 and Igf1 levels in PSCs isolated from wild-type mice and three mouse PDAC cell lines, highlighting the differential expression patterns. (B) Schematic diagram shows the therapeutic strategy of combining IGF1R inhibitor and AGR2-neutralizing antibody. (C) ELISA and qRT-PCR analyses demonstrate Igf1 levels in PSCs co-cultured with KPC PDAC-derived organoids. The impact of treatments with the IGF1R inhibitor (PPP; 1 μM), Agr2-neutralizing antibody (5 μg/mL) alone, or their combination for 48 h is shown ( n = 3 independent experiments). (D) Western blot results display the expression levels of p-Igf1r, Igf1r, c-Jun, p-c-Jun, Akt, p-Akt, Erk, p-Erk, and Agr2 in mouse PDAC-derived organoids after co-culture with PSC cells and subsequent treatments as mentioned in (C) ( n = 3 independent experiments). (E) Representative images and quantitative analyses show the growth dynamics of PDAC organoids co-cultured with PSC cells under various treatment conditions over 0, 24, 48, and 96 h (scale bars: 50 μm, n = 3 independent experiments). (F) Tumor volume comparisons in KPC mice post caerulein-induced acute pancreatitis and subsequent treatments with Agr2 antibody (4 mg/kg; intraperitoneally [i.p.], three times per week for 2 weeks), PPP (20 mg/kg; i.p., three times per week for 2 weeks), or their combination ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (G) ELISA quantification of Agr2, Igf1, Il-1α, Lif, GM-CSF, and Il-6 in serum samples from the four groups of KPC mice underscores the systemic effects of the treatment modalities on cytokine levels ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (H and I) Representative stained sections and quantitative statistics of H&E, Pdpn, α-SMA, collagen, Cd3, Cd4, Foxp3, B220, and Cd206-positive cells within PDAC tumors (scale bars: 50 μm, n = 5 mice per group). (J) Representative IHC highlights CD8-positive cells in lymph nodes adjacent to the tumors (scale bars: 50 μm). p values in (C), (F), and (G) were calculated using a one-way ANOVA with a multiple comparisons test, and p values in (H) and (I) were calculated using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet: Combined targeting attenuates desmoplastic reaction and normalizes immunosuppressive microenvironment (A) Western blot analysis reveals Agr2 and Igf1 levels in PSCs isolated from wild-type mice and three mouse PDAC cell lines, highlighting the differential expression patterns. (B) Schematic diagram shows the therapeutic strategy of combining IGF1R inhibitor and AGR2-neutralizing antibody. (C) ELISA and qRT-PCR analyses demonstrate Igf1 levels in PSCs co-cultured with KPC PDAC-derived organoids. The impact of treatments with the IGF1R inhibitor (PPP; 1 μM), Agr2-neutralizing antibody (5 μg/mL) alone, or their combination for 48 h is shown ( n = 3 independent experiments). (D) Western blot results display the expression levels of p-Igf1r, Igf1r, c-Jun, p-c-Jun, Akt, p-Akt, Erk, p-Erk, and Agr2 in mouse PDAC-derived organoids after co-culture with PSC cells and subsequent treatments as mentioned in (C) ( n = 3 independent experiments). (E) Representative images and quantitative analyses show the growth dynamics of PDAC organoids co-cultured with PSC cells under various treatment conditions over 0, 24, 48, and 96 h (scale bars: 50 μm, n = 3 independent experiments). (F) Tumor volume comparisons in KPC mice post caerulein-induced acute pancreatitis and subsequent treatments with Agr2 antibody (4 mg/kg; intraperitoneally [i.p.], three times per week for 2 weeks), PPP (20 mg/kg; i.p., three times per week for 2 weeks), or their combination ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (G) ELISA quantification of Agr2, Igf1, Il-1α, Lif, GM-CSF, and Il-6 in serum samples from the four groups of KPC mice underscores the systemic effects of the treatment modalities on cytokine levels ( n = 5 for control group, n = 3 for single treatment groups, and n = 5 for combined treatment group). (H and I) Representative stained sections and quantitative statistics of H&E, Pdpn, α-SMA, collagen, Cd3, Cd4, Foxp3, B220, and Cd206-positive cells within PDAC tumors (scale bars: 50 μm, n = 5 mice per group). (J) Representative IHC highlights CD8-positive cells in lymph nodes adjacent to the tumors (scale bars: 50 μm). p values in (C), (F), and (G) were calculated using a one-way ANOVA with a multiple comparisons test, and p values in (H) and (I) were calculated using two-tailed, unpaired Student’s t tests. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Western Blot, Isolation, Expressing, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Cell Culture, Derivative Assay, Co-Culture Assay, Control, Staining, Two Tailed Test

    Journal: Cell Reports Medicine

    Article Title: Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy

    doi: 10.1016/j.xcrm.2024.101927

    Figure Lengend Snippet:

    Article Snippet: Mouse monoclonal anti-AGR2 , Santa Cruz Biotechnology , Cat# sc-101211; RRID: AB_2225121.

    Techniques: Virus, Recombinant, Control, Enzyme-linked Immunosorbent Assay, Isolation, Membrane, Protein Extraction, Chromatin Immunoprecipitation, Bicinchoninic Acid Protein Assay, Sircol Collagen Assay, Luciferase, RNA Sequencing Assay, Sequencing, Expressing, Real-time Polymerase Chain Reaction, shRNA, Plasmid Preparation, Software, Flow Cytometry

    A IRE1β and AGR2 expression in cell lines. Proteins were extracted and probed for IRE1β expression and AGR2 expression via immunoblot. Tubulin was used as a loading control. B Photographs showing the phenotype of cultures overexpressing IRE1β-FLAG in IRE1α wild-type ( ERN1 +/+ ) and IRE1α deficient ( ERN1 -/- ) cells. Left panels show untreated cultures, middle panels show cultures treated with 1μg/ml doxycycline for 72 hours, right panels show cultures treated with both 1μg/ml doxycycline and 1μM IRE1 endonuclease inhibitor 4μ8C. C Quantification of IRE1β transgene expression over time in Calu-1 ERN -/-IRE1βFLAG-DOX and LS174T ERN -/- IRE1βFLAG-DOX cells by western blot. Cultures were treated with 1μg/ml doxycycline for the indicated times, protein lysates were probed for IRE1β-FLAG expression and tubulin as a loading control.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A IRE1β and AGR2 expression in cell lines. Proteins were extracted and probed for IRE1β expression and AGR2 expression via immunoblot. Tubulin was used as a loading control. B Photographs showing the phenotype of cultures overexpressing IRE1β-FLAG in IRE1α wild-type ( ERN1 +/+ ) and IRE1α deficient ( ERN1 -/- ) cells. Left panels show untreated cultures, middle panels show cultures treated with 1μg/ml doxycycline for 72 hours, right panels show cultures treated with both 1μg/ml doxycycline and 1μM IRE1 endonuclease inhibitor 4μ8C. C Quantification of IRE1β transgene expression over time in Calu-1 ERN -/-IRE1βFLAG-DOX and LS174T ERN -/- IRE1βFLAG-DOX cells by western blot. Cultures were treated with 1μg/ml doxycycline for the indicated times, protein lysates were probed for IRE1β-FLAG expression and tubulin as a loading control.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Expressing, Western Blot, Control

    A Verification of transgene expression and successful immunoprecipitation of FLAG-tagged IRE1 in the samples analyzed by MS in B and C. Lysates were probed for IRE1-FLAG expression using anti-FLAG, and actin was used as a loading control. B Proteins with a log 2 FC enrichment of >2 and log 10 Adj p-val of >2 for IRE1α-FLAG and IRE1β-FLAG immunoprecipitation (IP) compared to control cells. The Venn diagram shows the number of proteins that were detected uniquely associated with one of the two IRE1 paralogues or that were commonly identified with both IRE1 paralogues. C Volcano plot depicting the cutoff criteria and significantly enriched proteins in each IP. X-axis shows the log 2 fold change of the measured peptide intensities of a given protein in the control condition over the IRE1 IP condition. Y-axis shows the FDR corrected p-value obtained by two sample t-test in Perseus. D Confirmation of specific interaction between AGR2 and IRE1β, but not IRE1α. IRE1 proteins were tagged with an Avi-tag that is specifically biotinylated upon BirA co-expression. The biotinylated Avi-tag was precipitated using streptavidin beads. For control conditions, BirA was omitted. Blots were probed for co-precipitation of AGR2 and streptavidin to detect Avi-tag biotinylated IRE1. Tubulin was used as a loading control. Representative of 2 independent experiments. E Confirmation of the AGR2-IRE1β interaction in murine tissue. Colons were isolated and digested, and IP was performed using anti-AGR2. Agr2 deficient mice were used as a negative control to assess whether IRE1β binds aspecifically to the antibody/bead complex. IP samples were probed for IRE1β co-precipitation via immunoblot. Tubulin was used as a loading control.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A Verification of transgene expression and successful immunoprecipitation of FLAG-tagged IRE1 in the samples analyzed by MS in B and C. Lysates were probed for IRE1-FLAG expression using anti-FLAG, and actin was used as a loading control. B Proteins with a log 2 FC enrichment of >2 and log 10 Adj p-val of >2 for IRE1α-FLAG and IRE1β-FLAG immunoprecipitation (IP) compared to control cells. The Venn diagram shows the number of proteins that were detected uniquely associated with one of the two IRE1 paralogues or that were commonly identified with both IRE1 paralogues. C Volcano plot depicting the cutoff criteria and significantly enriched proteins in each IP. X-axis shows the log 2 fold change of the measured peptide intensities of a given protein in the control condition over the IRE1 IP condition. Y-axis shows the FDR corrected p-value obtained by two sample t-test in Perseus. D Confirmation of specific interaction between AGR2 and IRE1β, but not IRE1α. IRE1 proteins were tagged with an Avi-tag that is specifically biotinylated upon BirA co-expression. The biotinylated Avi-tag was precipitated using streptavidin beads. For control conditions, BirA was omitted. Blots were probed for co-precipitation of AGR2 and streptavidin to detect Avi-tag biotinylated IRE1. Tubulin was used as a loading control. Representative of 2 independent experiments. E Confirmation of the AGR2-IRE1β interaction in murine tissue. Colons were isolated and digested, and IP was performed using anti-AGR2. Agr2 deficient mice were used as a negative control to assess whether IRE1β binds aspecifically to the antibody/bead complex. IP samples were probed for IRE1β co-precipitation via immunoblot. Tubulin was used as a loading control.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Expressing, Immunoprecipitation, Control, Isolation, Negative Control, Western Blot

    A AGR2 transcript expression in cell lines assayed by RT-qPCR. Cultures were sampled at three different time points and AGR2 expression is shown relative to the expression detected in LS174T parental cells. B Quantification of IRE1β-FLAG transgene expression over time by western blot in cell lysates derived from Calu-1 ERN -/-IRE1βFLAG-DOX co-expressing ER-targeted BirA as a control protein (left, orange), or AGR2 (right, purple). Cells received 1μg/ml doxycycline to induce expression of IRE1β. Protein lysates were prepared at the indicated times and probed for IRE1β-FLAG expression, XBP1S and tubulin as a loading control. C Gating strategy to assess cell death. Doublets were gated out and dead cells were gated on via AnnexinV and Live/Dead positive staining. All cells staining positive for a single, or both cell death markers were considered dead (red gate).

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A AGR2 transcript expression in cell lines assayed by RT-qPCR. Cultures were sampled at three different time points and AGR2 expression is shown relative to the expression detected in LS174T parental cells. B Quantification of IRE1β-FLAG transgene expression over time by western blot in cell lysates derived from Calu-1 ERN -/-IRE1βFLAG-DOX co-expressing ER-targeted BirA as a control protein (left, orange), or AGR2 (right, purple). Cells received 1μg/ml doxycycline to induce expression of IRE1β. Protein lysates were prepared at the indicated times and probed for IRE1β-FLAG expression, XBP1S and tubulin as a loading control. C Gating strategy to assess cell death. Doublets were gated out and dead cells were gated on via AnnexinV and Live/Dead positive staining. All cells staining positive for a single, or both cell death markers were considered dead (red gate).

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Derivative Assay, Control, Staining

    Calu-1 ERN -/-IRE1βFLAG-DOX cells were transduced with a constitutive AGR2 transgene (“Calu-1 AGR “). Cells denoted as “Calu-1” are the original Calu-1 ERN -/-IRE1βFLAG-DOX cells. A RT-qPCR analysis of XBP1 S/T and BLOC1S1 transcript levels after 24 hours of transgene induction using 1 μg/ml doxycycline. Bottom picture shows XBP1 splicing in the same samples assayed by conventional PCR. Representative of three independent experiments with three replicates per condition. B Photographs showing the phenotype of cultures overexpressing IRE1β-FLAG with and without exogenous expression of AGR2. Left panels show untreated cultures, middle panels show cultures that received 1μg/ml doxycycline for 72 hours, cultures in the right panels received 1μg/ml doxycycline and 1μM 4μ8C. Representative of three independent experiments. C Quantification of cell death in cultures overexpressing IRE1β-FLAG with and without exogenously added AGR2 after 48 hours. All cells in the culture dish were stained with AnnexinV and Live/Dead stain and analyzed by flow cytometry. All single and double positive cells were considered as dead cells. Representative of 2 independent experiments with three replicates per condition. D Analysis of IRE1β-FLAG and AGR2 expression in the cell lines used for C. Only cells that remained attached in the dish were collected and lysates were probed for IRE1β expression using anti-FLAG and AGR2 expression using anti-AGR2. Tubulin was used as a loading control. E Validation of AGR2 knockdown efficiency in LS174T ERN -/-IRE1βFLAG-DOX cells. NTC is a non-targeting control pool of siRNA’s, #1 and #3 are siRNA’s targeting AGR2. F Changes in XBP1 splicing after AGR2 partial knockdown and/or treatment with 4μ8C or DMSO (vehicle). Splicing is shown as a log 2 fold change over the NTC/vehicle treated cells. E and F are representative of three independent experiments with three replicates per condition. G Western blot confirmation of (E) and (F). Proteins were extracted after 72 hours and probed for XBP1S, AGR2 and tubulin expression.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: Calu-1 ERN -/-IRE1βFLAG-DOX cells were transduced with a constitutive AGR2 transgene (“Calu-1 AGR “). Cells denoted as “Calu-1” are the original Calu-1 ERN -/-IRE1βFLAG-DOX cells. A RT-qPCR analysis of XBP1 S/T and BLOC1S1 transcript levels after 24 hours of transgene induction using 1 μg/ml doxycycline. Bottom picture shows XBP1 splicing in the same samples assayed by conventional PCR. Representative of three independent experiments with three replicates per condition. B Photographs showing the phenotype of cultures overexpressing IRE1β-FLAG with and without exogenous expression of AGR2. Left panels show untreated cultures, middle panels show cultures that received 1μg/ml doxycycline for 72 hours, cultures in the right panels received 1μg/ml doxycycline and 1μM 4μ8C. Representative of three independent experiments. C Quantification of cell death in cultures overexpressing IRE1β-FLAG with and without exogenously added AGR2 after 48 hours. All cells in the culture dish were stained with AnnexinV and Live/Dead stain and analyzed by flow cytometry. All single and double positive cells were considered as dead cells. Representative of 2 independent experiments with three replicates per condition. D Analysis of IRE1β-FLAG and AGR2 expression in the cell lines used for C. Only cells that remained attached in the dish were collected and lysates were probed for IRE1β expression using anti-FLAG and AGR2 expression using anti-AGR2. Tubulin was used as a loading control. E Validation of AGR2 knockdown efficiency in LS174T ERN -/-IRE1βFLAG-DOX cells. NTC is a non-targeting control pool of siRNA’s, #1 and #3 are siRNA’s targeting AGR2. F Changes in XBP1 splicing after AGR2 partial knockdown and/or treatment with 4μ8C or DMSO (vehicle). Splicing is shown as a log 2 fold change over the NTC/vehicle treated cells. E and F are representative of three independent experiments with three replicates per condition. G Western blot confirmation of (E) and (F). Proteins were extracted after 72 hours and probed for XBP1S, AGR2 and tubulin expression.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Transduction, Quantitative RT-PCR, Expressing, Staining, Flow Cytometry, Control, Biomarker Discovery, Knockdown, Western Blot

    A Schematic overview of gel filtration experiments in B and C. B msfGFP fluorescence measured during elution of HEK293T lysates overexpressing IRE1β in absence of AGR2 (black dotted trace) or in presence of AGR2 (orange and purple traces indicating different ratios of transfected AGR2:IRE1β plasmid). Top scale represents approximate elution profile and expected MW of protein standards. Bottom drawings indicate expected oligomerization status based on protein standards and the previously obtained elution profile (Grey). Experiment performed once. C IRE1β-FLAG expression in fractions collected after gel filtration of protein lysates from Calu-1 ERN -/- IRE1βFLAG-DOX cells, in the absence or presence of additional AGR2 expression. Line graph shows quantification of band intensities from the gel. Representative of two independent experiments. D Schematic representation of competition IP experiments in E and F. IRE1β is expressed with an Avi-tag or FLAG tag in equimolar amounts. After biotinylation of the Avi-tag by BirA, both the Avi-tag and FLAG-tag will be detected after streptavidin IP if dimers have been formed. If addition of another protein ( e.g. AGR2) would block this process, a loss of signal is expected. E Competition IP showing loss of dimer formation upon co-expression of AGR2. Samples were immunoblotted with anti-AGR2, anti-FLAG and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments. F Competition IP demonstrating concentration-dependent loss of dimer formation upon increasing AGR2 co-expression. Samples were immunoblotted with anti-AGR2, anti-FLAG and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A Schematic overview of gel filtration experiments in B and C. B msfGFP fluorescence measured during elution of HEK293T lysates overexpressing IRE1β in absence of AGR2 (black dotted trace) or in presence of AGR2 (orange and purple traces indicating different ratios of transfected AGR2:IRE1β plasmid). Top scale represents approximate elution profile and expected MW of protein standards. Bottom drawings indicate expected oligomerization status based on protein standards and the previously obtained elution profile (Grey). Experiment performed once. C IRE1β-FLAG expression in fractions collected after gel filtration of protein lysates from Calu-1 ERN -/- IRE1βFLAG-DOX cells, in the absence or presence of additional AGR2 expression. Line graph shows quantification of band intensities from the gel. Representative of two independent experiments. D Schematic representation of competition IP experiments in E and F. IRE1β is expressed with an Avi-tag or FLAG tag in equimolar amounts. After biotinylation of the Avi-tag by BirA, both the Avi-tag and FLAG-tag will be detected after streptavidin IP if dimers have been formed. If addition of another protein ( e.g. AGR2) would block this process, a loss of signal is expected. E Competition IP showing loss of dimer formation upon co-expression of AGR2. Samples were immunoblotted with anti-AGR2, anti-FLAG and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments. F Competition IP demonstrating concentration-dependent loss of dimer formation upon increasing AGR2 co-expression. Samples were immunoblotted with anti-AGR2, anti-FLAG and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Filtration, Fluorescence, Transfection, Plasmid Preparation, Expressing, FLAG-tag, Blocking Assay, Control, Concentration Assay

    A The structure of AGR2 (pdb: 2LNS) visualized in PyMol with the relevant mutations indicated. Purple and grey cartoons depict two AGR2 molecules and their dimer structure , specific residues are represented as ball-and-sticks. B Schematic overview of competition IP using AGR2 mutants. C Competition IP showing loss of dimer inhibition using C81S and H117Y AGR2 mutants. Samples were immunoblotted with anti-AGR2, anti-FLAG-IRE1β and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments. D Calu-1 ERN -/-IRE1βFLAG-DOX cells were transduced with a constitutive AGR2 transgene (wild-type or the indicated mutants) and IRE1β-FLAG overexpression was induced with 1μg/ml doxycycline for 72 hours. E Quantification of cell death in cell lines from D after 72 hours of transgene expression. All cells in the culture dish were stained with Annexin V and Live/Dead stain and analyzed by flow cytometry. All single and double positive cells were considered as dead cells. Representative of 2 independent experiments with two replicates.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A The structure of AGR2 (pdb: 2LNS) visualized in PyMol with the relevant mutations indicated. Purple and grey cartoons depict two AGR2 molecules and their dimer structure , specific residues are represented as ball-and-sticks. B Schematic overview of competition IP using AGR2 mutants. C Competition IP showing loss of dimer inhibition using C81S and H117Y AGR2 mutants. Samples were immunoblotted with anti-AGR2, anti-FLAG-IRE1β and Streptavidin. Tubulin was used as a loading control in input samples. Representative of two independent experiments. D Calu-1 ERN -/-IRE1βFLAG-DOX cells were transduced with a constitutive AGR2 transgene (wild-type or the indicated mutants) and IRE1β-FLAG overexpression was induced with 1μg/ml doxycycline for 72 hours. E Quantification of cell death in cell lines from D after 72 hours of transgene expression. All cells in the culture dish were stained with Annexin V and Live/Dead stain and analyzed by flow cytometry. All single and double positive cells were considered as dead cells. Representative of 2 independent experiments with two replicates.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Inhibition, Control, Transduction, Over Expression, Expressing, Staining, Flow Cytometry

    A AGR2 expression in cultures analyzed in Fig 5D and 5E. Tubulin was used as a loading control.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A AGR2 expression in cultures analyzed in Fig 5D and 5E. Tubulin was used as a loading control.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Expressing, Control

    A BLAST alignment of the regions containing cysteines in human IRE1α and IRE1β. Green square indicates the sole conserved cysteine in IRE1α and IRE1β luminal domain, orange squares show cysteines present in only one of the paralogues. B Highest scoring AlphaFold2-Multimer model (pTM score = 0.662), modeled using IRE1β residues 35-377 (Uniprot Q76MJ5) and AGR2 residues 41-175 (Uniprot O95994). The IRE1β luminal domain is shown in orange and AGR2 in grey. Labels indicate the highlighted green residues. C Predicted aligned error (PAE) plot for the model shown in B.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: A BLAST alignment of the regions containing cysteines in human IRE1α and IRE1β. Green square indicates the sole conserved cysteine in IRE1α and IRE1β luminal domain, orange squares show cysteines present in only one of the paralogues. B Highest scoring AlphaFold2-Multimer model (pTM score = 0.662), modeled using IRE1β residues 35-377 (Uniprot Q76MJ5) and AGR2 residues 41-175 (Uniprot O95994). The IRE1β luminal domain is shown in orange and AGR2 in grey. Labels indicate the highlighted green residues. C Predicted aligned error (PAE) plot for the model shown in B.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques:

    In steady state conditions, AGR2 is bound to most IRE1β molecules and under these conditions, IRE1β is mainly present in the inactive, monomeric forms. As a result, overall IRE1β activity will be low. In conditions where an activating trigger is present (possibly unfolded MUC2 polypeptides, though this remains to be demonstrated), AGR2 is released from IRE1β in favor of binding other AGR2 chaperone substrates. As a result, IRE1β is released, activated and overall IRE1β activity will be high. In case of AGR2 C81S and AGR2 H117 Y , interaction with IRE1β is disrupted leading to spontaneous IRE1β dimerization triggering its activity.

    Journal: bioRxiv

    Article Title: Activation of goblet cell stress sensor IRE1β is controlled by the mucin chaperone AGR2

    doi: 10.1101/2023.07.06.547951

    Figure Lengend Snippet: In steady state conditions, AGR2 is bound to most IRE1β molecules and under these conditions, IRE1β is mainly present in the inactive, monomeric forms. As a result, overall IRE1β activity will be low. In conditions where an activating trigger is present (possibly unfolded MUC2 polypeptides, though this remains to be demonstrated), AGR2 is released from IRE1β in favor of binding other AGR2 chaperone substrates. As a result, IRE1β is released, activated and overall IRE1β activity will be high. In case of AGR2 C81S and AGR2 H117 Y , interaction with IRE1β is disrupted leading to spontaneous IRE1β dimerization triggering its activity.

    Article Snippet: SDS-PAGE was performed with Mini-Protean TGX 4-20% gels (Bio-Rad), proteins were transferred to PVDF membrane (Amersham 0.2 Hybond P, Cytiva) and revealed using following antibodies: mouse AGR2 (Santa Cruz Biotechnology, Clone 6C5, 1/1000), rabbit IRE1β (gift from David Ron, University of Cambridge, 1/2000), rabbit β-Tubulin-HRP (Abcam, ab21058, 1/5000), mouse IgG-HRP (Dako, P0447, 1/1500) and rabbit IgG-HRP (Dako, P0448, 1/2000).

    Techniques: Activity Assay, Binding Assay

    Workflow of AGR2 pull-down (PD) methods and protein-level analysis. A, two different cell lines were used for AGR2 PD. Breast cancer cell line T47D, of which endogenously expressed AGR2 protein underwent DSP crosslinking and PD with AGR2-specific E7 peptide and untargeted control peptide F4. Cells without DSP treatment served as a control. Corresponding MS data were quantified using label-free quantification (LFQ). H1299 lung carcinoma cell line was stably transfected with vector carrying coding sequence of AGR2. AGR2 positive clone was labeled with heavy (R10K8) SILAC medium, whereas parental H1299 served as a control and was maintained in light (R0K0) SILAC medium. These cells underwent DSP crosslinking, and lysates were, according to total protein content, equally mixed into one sample, and PD was done with E7 (AGR2 specific) and F4 (control) peptides again. MS data were quantified using SILAC approach. B and C, protein levels of AGR2 were detected in all input samples (20 μg of total protein per well) as well as in eluted proteins (10 μl of eluates per well) using immunoblotting with anti-AGR2 and antiactin antibodies, which served as a loading control. Numbers under the bands represent integral absorbance (INT∗mm 2 ∗10 3 ) obtained by Quantity One software (Bio-Rad). AGR2, anterior gradient 2; DSP, dithiobis[succinimidylpropionate]; MS, mass spectrometry; SILAC, stable isotope labeling with amino acids in cell culture.

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Workflow of AGR2 pull-down (PD) methods and protein-level analysis. A, two different cell lines were used for AGR2 PD. Breast cancer cell line T47D, of which endogenously expressed AGR2 protein underwent DSP crosslinking and PD with AGR2-specific E7 peptide and untargeted control peptide F4. Cells without DSP treatment served as a control. Corresponding MS data were quantified using label-free quantification (LFQ). H1299 lung carcinoma cell line was stably transfected with vector carrying coding sequence of AGR2. AGR2 positive clone was labeled with heavy (R10K8) SILAC medium, whereas parental H1299 served as a control and was maintained in light (R0K0) SILAC medium. These cells underwent DSP crosslinking, and lysates were, according to total protein content, equally mixed into one sample, and PD was done with E7 (AGR2 specific) and F4 (control) peptides again. MS data were quantified using SILAC approach. B and C, protein levels of AGR2 were detected in all input samples (20 μg of total protein per well) as well as in eluted proteins (10 μl of eluates per well) using immunoblotting with anti-AGR2 and antiactin antibodies, which served as a loading control. Numbers under the bands represent integral absorbance (INT∗mm 2 ∗10 3 ) obtained by Quantity One software (Bio-Rad). AGR2, anterior gradient 2; DSP, dithiobis[succinimidylpropionate]; MS, mass spectrometry; SILAC, stable isotope labeling with amino acids in cell culture.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Control, Quantitative Proteomics, Stable Transfection, Transfection, Plasmid Preparation, Sequencing, Labeling, Multiplex sample analysis, Western Blot, Software, Mass Spectrometry, Cell Culture

    Annotation of AGR2 protein–protein complexes in relation to cell signaling. Top 20 protein–protein interacting partners of AGR2 (log2FC >0; q < 0.05) identified in ( A ) T47D cells using LFQ and ( B ) H1299–AGR2 cells using SILAC quantitation. See and for source data for A and B , respectively. Proteins in red are members of the PDI family, proteins in blue are not members. C, 151 and 22 proteins (log2FC >0; q < 0.05) were identified as AGR2-interacting partners in T47D and H1299–AGR2 cells, respectively. Comparison of these proteins between cell lines has selected 16 overlapping proteins ( <xref ref-type=supplemental Table S1 ). PDI members are highlighted in red . D, Cytoscape ClueGO analysis (based on GO and KEGG pathway databases) of 16 overlapping proteins ( supplemental Table S1 ) has revealed a clear connection of proteins to the ER and ER processes. Enriched GO and KEGG terms are represented by nodes, and protein overlap between the terms is displayed by edges. Similarly, analysis of 16 overlapping proteins ( supplemental Table S1 ) with ConsensusPathDB-human tool with GO and KEGG databases clearly showed strong connection to ( E ) biological processes running in ER highlighted in blue box and to ( F ) molecular functions associated with protein translation and folding in ER, all pathways with p value <0.001 as determined by ConsensusPathDB-human tool. AGR2, anterior gradient 2; ER, endoplasmic reticulum; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LFQ, label-free quantitation; log2FC, log2 fold change; PDI, protein disulfide isomerase; SILAC, stable isotope labeling with amino acids in cell culture. " width="100%" height="100%">

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Annotation of AGR2 protein–protein complexes in relation to cell signaling. Top 20 protein–protein interacting partners of AGR2 (log2FC >0; q < 0.05) identified in ( A ) T47D cells using LFQ and ( B ) H1299–AGR2 cells using SILAC quantitation. See and for source data for A and B , respectively. Proteins in red are members of the PDI family, proteins in blue are not members. C, 151 and 22 proteins (log2FC >0; q < 0.05) were identified as AGR2-interacting partners in T47D and H1299–AGR2 cells, respectively. Comparison of these proteins between cell lines has selected 16 overlapping proteins ( supplemental Table S1 ). PDI members are highlighted in red . D, Cytoscape ClueGO analysis (based on GO and KEGG pathway databases) of 16 overlapping proteins ( supplemental Table S1 ) has revealed a clear connection of proteins to the ER and ER processes. Enriched GO and KEGG terms are represented by nodes, and protein overlap between the terms is displayed by edges. Similarly, analysis of 16 overlapping proteins ( supplemental Table S1 ) with ConsensusPathDB-human tool with GO and KEGG databases clearly showed strong connection to ( E ) biological processes running in ER highlighted in blue box and to ( F ) molecular functions associated with protein translation and folding in ER, all pathways with p value <0.001 as determined by ConsensusPathDB-human tool. AGR2, anterior gradient 2; ER, endoplasmic reticulum; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LFQ, label-free quantitation; log2FC, log2 fold change; PDI, protein disulfide isomerase; SILAC, stable isotope labeling with amino acids in cell culture.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Multiplex sample analysis, Quantitation Assay, Comparison, Quantitative Proteomics, Cell Culture

    AGR2, PDIA3, and PDIA6 protein levels in E7  (AGR2-specific  peptide) native eluates from DSP-crosslinked H1299 cells stably transfected with AGR2 gene compared with F4 (control) native eluates from the same cells

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: AGR2, PDIA3, and PDIA6 protein levels in E7 (AGR2-specific peptide) native eluates from DSP-crosslinked H1299 cells stably transfected with AGR2 gene compared with F4 (control) native eluates from the same cells

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Stable Transfection, Transfection, Control, Sequencing, Molecular Weight

    Immunofluorescence microscopy of PDIA3 and PDIA6 in relation to AGR2. Immunofluorescence staining of AGR2 ( red ) in parallel with ( A ) PDIA3 ( green ) and ( B ) PDIA6 ( green ). Merged images show colocalization of these proteins indicating the presence of AGR2–PDIA3 and AGR2–PDIA6 complexes. Nucleic staining ( blue ) was done by Hoechst 33342. The scale bar represents 10 μm. Colocalization of fluorescence signals was determined by Pearson's correlation coefficient (graphs on the right side ). See <xref ref-type=supplemental Fig. S1 for a positive colocalization control. AGR2, anterior gradient 2; PDIA3, protein disulfide isomerase A3. " width="100%" height="100%">

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Immunofluorescence microscopy of PDIA3 and PDIA6 in relation to AGR2. Immunofluorescence staining of AGR2 ( red ) in parallel with ( A ) PDIA3 ( green ) and ( B ) PDIA6 ( green ). Merged images show colocalization of these proteins indicating the presence of AGR2–PDIA3 and AGR2–PDIA6 complexes. Nucleic staining ( blue ) was done by Hoechst 33342. The scale bar represents 10 μm. Colocalization of fluorescence signals was determined by Pearson's correlation coefficient (graphs on the right side ). See supplemental Fig. S1 for a positive colocalization control. AGR2, anterior gradient 2; PDIA3, protein disulfide isomerase A3.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Immunofluorescence, Microscopy, Staining, Fluorescence, Control

    Validation of PDIA3 and PDIA6 as AGR2-interacting partners. The combined procedures of IP and SDS-PAGE were used in complex protein mixtures from T47D cells either exposed or unexposed to DSP in order to ( A ) precipitate AGR2 by specific antibody (s); ( B ) precipitate PDIA3 ( left part ) and PDIA6 ( right part ) by specific antibodies (s). Nonspecific antibody (ns) served as a negative control ( third line ). C, PLA images of complexes AGR2–PDIA3/6: red signals emerge only when proteins are closely localized. Nucleic staining ( blue ) was done by DAPI. The scale bar represents 20 μm. See <xref ref-type=supplemental Fig. S5 for corresponding PLA results in H1299 and A549 cell lines. AGR2, anterior gradient 2; DAPI, 4′,6-diamidino-2-phenylindole; IP, immunoprecipitation; PDIA, protein disulfide isomerase A; PLA, proximity ligation assay. " width="100%" height="100%">

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Validation of PDIA3 and PDIA6 as AGR2-interacting partners. The combined procedures of IP and SDS-PAGE were used in complex protein mixtures from T47D cells either exposed or unexposed to DSP in order to ( A ) precipitate AGR2 by specific antibody (s); ( B ) precipitate PDIA3 ( left part ) and PDIA6 ( right part ) by specific antibodies (s). Nonspecific antibody (ns) served as a negative control ( third line ). C, PLA images of complexes AGR2–PDIA3/6: red signals emerge only when proteins are closely localized. Nucleic staining ( blue ) was done by DAPI. The scale bar represents 20 μm. See supplemental Fig. S5 for corresponding PLA results in H1299 and A549 cell lines. AGR2, anterior gradient 2; DAPI, 4′,6-diamidino-2-phenylindole; IP, immunoprecipitation; PDIA, protein disulfide isomerase A; PLA, proximity ligation assay.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Biomarker Discovery, SDS Page, Negative Control, Staining, Immunoprecipitation, Proximity Ligation Assay

    The effect of ER inducers on AGR2–PDIA3 complex formation. Changes in subcellular localization of AGR2–PDIA3 complex in response to tunicamycin (TUN) and thapsigargin (THG) in comparison with untreated (control, CTR) ( A ) T47D and ( B ) A549 cells were analyzed using immunofluorescence staining for AGR2 ( green ), PDIA3 ( red ), and nucleus by DAPI ( blue ). The scale bar represents 10 μm. Colocalization of fluorescence signals was determined by Pearson's correlation coefficient, nonparametric one-way ANOVA (Kruskal–Wallis test with Dunn correction) test was used to calculate the statistical significance, ∗∗∗ p ≤ 0.001. AGR2, anterior gradient 2; DAPI, 4′,6-diamidino-2-phenylindole; ER, endoplasmic reticulum; ns, nonsignificant; PDIA3, protein disulfide isomerase A3.

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: The effect of ER inducers on AGR2–PDIA3 complex formation. Changes in subcellular localization of AGR2–PDIA3 complex in response to tunicamycin (TUN) and thapsigargin (THG) in comparison with untreated (control, CTR) ( A ) T47D and ( B ) A549 cells were analyzed using immunofluorescence staining for AGR2 ( green ), PDIA3 ( red ), and nucleus by DAPI ( blue ). The scale bar represents 10 μm. Colocalization of fluorescence signals was determined by Pearson's correlation coefficient, nonparametric one-way ANOVA (Kruskal–Wallis test with Dunn correction) test was used to calculate the statistical significance, ∗∗∗ p ≤ 0.001. AGR2, anterior gradient 2; DAPI, 4′,6-diamidino-2-phenylindole; ER, endoplasmic reticulum; ns, nonsignificant; PDIA3, protein disulfide isomerase A3.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Comparison, Control, Immunofluorescence, Staining, Fluorescence

    ER stress induces complex formation followed by enhanced secretion of AGR2. Immunochemical analysis of ( A ) intracellular and ( B ) extracellular AGR2 and PDIA3 in response to induction of ER stress. The numbers under the boxes represent relative fold changes in absorbance reflecting protein levels normalized on intracellular actin density of treated cells in relation to serum-starved cells (serum-free media [SFM]). C, IP of AGR2–PDIA3 complexes followed by SDS-PAGE in cells exposed to different inducers of ER stress. D, subcellular protein fractionation of several ER-resident proteins in A549 and T47D cells treated with ER stress inducers. The numbers under the boxes represent fold changes in absorbance reflecting protein levels normalized on GAPDH density of treated cells in relation to DMSO-exposed cells. PDIA3∗ represents the same experiment however, with prolonged exposition time to show redistribution of PDIA3 to the cytosol. Each experiment was performed at least three times. Average fold changes along with standard deviations are shown in <xref ref-type=supplemental Fig. S6 . AGR2, anterior gradient 2; CF, cytosolic fraction; DMSO, dimethyl sulfoxide; ER, membrane bound fraction containing endoplasmic reticulum; IP, immunoprecipitation; PDIA3, protein disulfide isomerase A3; WL, whole lysate. " width="100%" height="100%">

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: ER stress induces complex formation followed by enhanced secretion of AGR2. Immunochemical analysis of ( A ) intracellular and ( B ) extracellular AGR2 and PDIA3 in response to induction of ER stress. The numbers under the boxes represent relative fold changes in absorbance reflecting protein levels normalized on intracellular actin density of treated cells in relation to serum-starved cells (serum-free media [SFM]). C, IP of AGR2–PDIA3 complexes followed by SDS-PAGE in cells exposed to different inducers of ER stress. D, subcellular protein fractionation of several ER-resident proteins in A549 and T47D cells treated with ER stress inducers. The numbers under the boxes represent fold changes in absorbance reflecting protein levels normalized on GAPDH density of treated cells in relation to DMSO-exposed cells. PDIA3∗ represents the same experiment however, with prolonged exposition time to show redistribution of PDIA3 to the cytosol. Each experiment was performed at least three times. Average fold changes along with standard deviations are shown in supplemental Fig. S6 . AGR2, anterior gradient 2; CF, cytosolic fraction; DMSO, dimethyl sulfoxide; ER, membrane bound fraction containing endoplasmic reticulum; IP, immunoprecipitation; PDIA3, protein disulfide isomerase A3; WL, whole lysate.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: SDS Page, Fractionation, Membrane, Immunoprecipitation

    Binding interface classification of the top 10 solutions from monomer and dimer  AGR2  docking experiments to PDIA3

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Binding interface classification of the top 10 solutions from monomer and dimer AGR2 docking experiments to PDIA3

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Binding Assay

    Visualization of the interaction between AGR2 monomer and PDIA3. A representative of the best docking solution from GalaxyHeteromer experiment for monomeric AGR2 ( yellow ) is visualized in complex with PDIA3 ( gray ). N termini (Ile36) and C termini (Leu175) of ARG2 are indicated in light and purple solid van der Waals radii spheres, respectively. N termini (Ser25) and C termini (Glu493) of PDIA3 are indicated in light and dark blue solid van der Waals radii spheres , respectively. PDIA3 domains are labeled according to the description of the PDB file and following this legend: a-domain comprises residues Ser25–Gly133; b-domain comprises residues Pro134–Gly242; b'-domain comprises residues Ile243–Lys366; and a'-domain comprises residues Ser367–Ala484. Active site motifs are shown in red for both proteins; their sequences and residue numbers are indicated in proximity and with the same color code. AGR2, anterior gradient 2; PDB, Protein Data Bank; PDIA3, protein disulfide isomerase A3.

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: Visualization of the interaction between AGR2 monomer and PDIA3. A representative of the best docking solution from GalaxyHeteromer experiment for monomeric AGR2 ( yellow ) is visualized in complex with PDIA3 ( gray ). N termini (Ile36) and C termini (Leu175) of ARG2 are indicated in light and purple solid van der Waals radii spheres, respectively. N termini (Ser25) and C termini (Glu493) of PDIA3 are indicated in light and dark blue solid van der Waals radii spheres , respectively. PDIA3 domains are labeled according to the description of the PDB file and following this legend: a-domain comprises residues Ser25–Gly133; b-domain comprises residues Pro134–Gly242; b'-domain comprises residues Ile243–Lys366; and a'-domain comprises residues Ser367–Ala484. Active site motifs are shown in red for both proteins; their sequences and residue numbers are indicated in proximity and with the same color code. AGR2, anterior gradient 2; PDB, Protein Data Bank; PDIA3, protein disulfide isomerase A3.

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: Labeling, Residue

     AGR2-interacting  proteins overlapped in three independent studies (( <xref ref-type= 54 , 55 ) and ours)" width="100%" height="100%">

    Journal: Molecular & Cellular Proteomics : MCP

    Article Title: Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

    doi: 10.1016/j.mcpro.2021.100188

    Figure Lengend Snippet: AGR2-interacting proteins overlapped in three independent studies (( 54 , 55 ) and ours)

    Article Snippet: In contrast, cells labeled with two different fluorochromes for AGR2 (obtained by anti-AGR2 mouse Ab from Abnova and anti-AGR2 rabbit Ab from Abcam followed by fluorochrome-conjugated secondary antibodies from Abcam mentioned previously) served as the positive control for determination of colocalization (mean Pearson's correlation coefficient = 0.93).

    Techniques: